Spinal & fracture-fixation hardware
Spinal and fracture-fixation hardware infections are among the hardest implant-associated infections to cure: bacteria form antibiotic-tolerant biofilms on titanium and steel, and when the implant cannot be removed (e.g., to maintain spinal stability or fracture union), surgeons are left with prolonged, often-failing suppressive antibiotics. These infections are frequently polymicrobial, mixing Staphylococcus aureus/epidermidis, Cutibacterium acnes, Pseudomonas aeruginosa, and Enterobacterales, which compounds antimicrobial resistance and biofilm tolerance. Lytic bacteriophages are well suited here because they self-amplify at the infection site, actively penetrate and degrade biofilm matrix, kill metabolically dormant biofilm-embedded cells that antibiotics miss, and can be combined as multi-phage cocktails to cover several co-infecting species simultaneously. As a personalized, implant-sparing adjunct delivered locally or intravenously alongside debridement and antibiotics, phage therapy targets exactly the recalcitrance that makes hardware infection so refractory.
How phages act here
Mechanism
Lytic phages bind host-specific surface receptors, inject their genome, hijack bacterial machinery, and lyse the cell while releasing progeny that propagate the kill at the implant surface. Against the polymicrobial biofilms on spinal and fracture hardware, three mechanisms are central: (1) strain/species specificity guided by phagograms allows a curated cocktail to cover multiple co-pathogens (e.g., S. aureus plus P. aeruginosa or C. acnes) without disrupting commensals; (2) biofilm penetration via phage-encoded depolymerases and lysins that degrade extracellular polysaccharide and expose embedded cells on titanium; and (3) phage-antibiotic synergy (PAS), where sublethal antibiotic exposure enhances phage replication and phages re-sensitize biofilm bacteria to drugs they otherwise tolerate. Cocktails and PAS also suppress emergence of phage-resistant mutants. Adjacent engineered approaches include chimeric endolysins and depolymerase enzybiotics (bacteriophage-derived enzymes) that rapidly lyse biofilm and staphylococcal abscess communities, and CRISPR/synthetic-biology phage engineering to broaden host range and re-sensitize resistant strains, though these remain largely preclinical for hardware infection.
Where it stands
Current evidence
As of 2026 the evidence is early-stage: strong preclinical/animal data plus a growing body of compassionate-use case reports and small registries, but no completed randomized controlled trials specific to spinal or fracture-fixation hardware. A landmark 2025 case report (Arientová et al., Military University Hospital Prague) described the first successful systemic phage therapy for implant-associated MRSA spondylodiscitis with non-removable spinal instrumentation: 35 IV doses of an individualized antistaphylococcal phage at 10^9 PFU, regulator-approved, with sustained remission and normalized inflammatory markers six months after stopping all antibiotics. In a controlled 2025 sheep fracture-related infection model (tibial osteotomy with plate fixation; Peez et al., AO Research Institute Davos/Leuven), IV and local phage plus vancomycin were safe but limited by rapid phage clearance and host neutralization (up to 99.9%), underscoring that phages are an adjunct, not a standalone. In vitro, optimized cocktails disrupted C. acnes biofilm on titanium discs mimicking the implant environment (Chen et al., 2024). Pioneering Leuven case series (Onsea et al., 2019 onward) treated chronic osteomyelitis including polymicrobial cases (P. aeruginosa + S. epidermidis) with local phage cocktails. Clinical activity is now centralized in dedicated programs and the prospective PHAGEFORCE registry (NCT06368388), recruiting last-resort musculoskeletal infection patients.
Evidence confidence: low
The data
Key studies & trials
- Arientová S, Beran O, Belšan T, Holub M. Successful systemic phage therapy for implant-associated MRSA spondylodiscitis. International Journal of Infectious Diseases. 2025;164:108357. (Case report: 60-year-old with chronic MRSA vertebral osteomyelitis and non-removable spinal instrumentation; 35 IV phage doses, sustained remission off antibiotics at 6 months.) ↗
- Peez C, Chen B, Henssler L, et al. Evaluating the safety, pharmacokinetics and efficacy of phage therapy in treating fracture-related infections with multidrug-resistant Staphylococcus aureus: intravenous versus local application in sheep. Frontiers in Cellular and Infection Microbiology. 2025;15:1547250. (Sheep tibial plate-fixation FRI model; phage + vancomycin; rapid clearance and neutralization observed.) ↗
- Chen B, Chittò M, Tao S, Wagemans J, Lavigne R, Richards RG, Metsemakers WJ, Moriarty TF. Isolation and Antibiofilm Activity of Bacteriophages against Cutibacterium acnes from Patients with Periprosthetic Joint Infection. Viruses. 2024;16(10):1592. (Phage cocktail disrupts C. acnes biofilm on titanium discs modeling the implant environment.) ↗
- Foster AL, Moriarty TF, Trampuz A, et al. Fracture-related infection: current methods for prevention and treatment. Expert Review of Anti-infective Therapy. 2020;18(4):307-321. (Review covering FRI management including bacteriophage therapy for drug-resistant organisms.) ↗
Who is working on it
Programs & centers
The possibility
Within the next decade, a patient with infected spinal hardware that cannot be removed could have a swab phagogram returned in days, then receive a personalized multi-phage cocktail dripped onto the implant during debridement and dosed intravenously to chase down each co-infecting species, all while the metalwork stays in place and the spine stays stable. Engineered and CRISPR-armed phages, paired with biofilm-cracking depolymerases and synergistic antibiotics, could turn today's last-resort salvage into a routine implant-sparing protocol that resolves polymicrobial biofilms without the morbidity of staged hardware removal. If the ongoing registries mature into controlled trials, phage cocktails may become the decisive tool that finally breaks the biofilm stalemate at the metal-bone interface.